The Productization of Telehealth

Executive Summary

For years, most telehealth companies sold treatments under generic names: sildenafil, sermorelin, TRT, HRT. ExploreTreatments set out to test a specific question: are telehealth companies now building proprietary, consumer-facing product brands underneath their master brand, rather than simply selling the underlying treatment?

We reviewed the public marketing of roughly 30 U.S. telehealth companies across men’s health, women’s health, weight management, and longevity, drawing on ExploreTreatments’ own verified provider research alongside independent web research conducted in September 2026. The pattern is real, but it is not evenly distributed: men’s sexual health has moved furthest, while sermorelin, NAD+, and TRT remain overwhelmingly generic.

1. Telehealth Is Starting to Name the Product

Telehealth marketing has historically leaned on the generic name of the underlying medication or treatment category: sildenafil, tadalafil, sermorelin, NAD+, TRT, HRT. A generic name is accurate, but it is also the same name every competitor can use.

An alternative structure is emerging in parts of the market: a master telehealth brand sells a proprietary, named product, which in turn is built on a generic underlying treatment.

BetterMe Rx’s QMAX is the clearest real-world example: BetterMe Rx is the telehealth company, QMAX is the named product, and a compounded 4-in-1 ED formula (sildenafil, tadalafil, vardenafil, and apomorphine) is what the patient actually receives. The medication itself is not made proprietary by the brand name: the name is the asset, not the formula.

2. The Telehealth Product Brand Map

The table below is ExploreTreatments’ verified brand map: every company, the product brand it markets (if any), the underlying treatment, and how we classify its naming model. Rows marked with an asterisk summarize a larger cohort ExploreTreatments already verified in a prior report, cited in the Methodology section below, rather than listing every individual provider again here.

*TRT and NAD+ rows summarize the 8-provider and 30-provider cohorts from ExploreTreatments’ own 2026 TRT Telehealth Pricing Report and The State of NAD+ Telehealth 2026.

3. Men's Health Is Leading the Shift

Men’s sexual health shows the clearest and most repeated pattern in this dataset. Nine of the companies reviewed sell a 4-in-1 (or 3-in-1, or 5-in-1) compounded ED formula under a short, brandable name rather than listing the active ingredients as the headline: QMAX, QUAD (used independently by two different companies), Charge, Ready, TEMPO, RODEO, Lucky WOW, and 4-MAX.

ExploreTreatments did not find evidence establishing why each company chose this path, so the following are hypotheses drawn from the pattern itself, not confirmed motivations:

• A multi-ingredient compounded formula is harder to describe in a headline than a single drug name: "QMAX" is easier to say than "sildenafil, tadalafil, vardenafil, and apomorphine."
• Individual PDE5 inhibitors can look interchangeable to a shopper; a distinct name creates a reason to remember one provider over another selling a similar formula.
• Sexual wellness already carries some consumer-product framing (packaging, flavor, discreet delivery), which lends itself to product naming more naturally than a clinical service does.
• A named product may be easier to build repeat-purchase loyalty around than a generic treatment category that any competitor can also advertise.

The MEDVi/FeelGood “QUAD” overlap is worth noting on its own: two unrelated telehealth companies market an unrelated 4-in-1 ED formula under the identical name QUAD. That is exactly the kind of collision a trademark clearance search is designed to catch before launch (see Section 8).

4. Women's Health Is Beginning to Follow

Women’s telehealth shows the same structural idea, but at a much earlier and narrower stage. DirectMeds markets its HRT bundle as Nuvella rather than simply “HRT”: a bundled bioidentical program (estrogen, progesterone, vaginal estrogen, and DHEA) under one named product and one flat price.

Fem Excel, operated by Excel Medical, markets a proprietary protocol it calls “The Excel Advantage™,” a named program rather than a named drug product, but the same underlying idea of building an identifiable brand layer above generic HRT.

Outside those two, the pattern does not hold yet. Four other prominent menopause and HRT telehealth brands ExploreTreatments reviewed (Midi Health, Alloy, Evernow, and Winona) all market hormone therapy under the company name itself, with no distinct product sub-brand identified in their public marketing. Women’s health, on this evidence, is beginning to follow men’s health, not matching it yet.

5. The Unbranded Opportunity

Three categories in ExploreTreatments’ existing research stand out for how little product branding appears in them at all: sermorelin, NAD+, and TRT.

6. Observed vs. Illustrative: Applying the Framework

The table below places every real market example from this report next to the illustrative, publisher-owned concept used to demonstrate the same architecture in a category where the pattern is weak or absent. The right-hand column is never evidence of market adoption.

7. Why Trademarking Changes the Equation

A company generally cannot claim exclusive trademark rights over the generic name of the underlying medication itself: no telehealth company can own the word “sermorelin” or “sildenafil.” A sufficiently distinctive product name is a different matter: it may potentially qualify for federal trademark protection, subject to clearance, likelihood-of-confusion analysis, the correct goods/services classification, actual use in commerce, and USPTO examination.

Trademark strength runs along a spectrum, and where a name falls on it matters more than whether a company simply files an application.

Generic and merely descriptive terms generally receive little or no trademark protection on their own. Suggestive, arbitrary, and fanciful marks are generally considered stronger and more likely to receive broader protection, according to USPTO guidance on trademark strength. This report does not make a legal determination that any specific name discussed here, including the illustrative publisher-owned names in Section 15, is registrable; that requires professional clearance.

Verify exact usage against current USPTO guidance before applying either symbol to a specific mark.

8. What Does a Product Trademark Actually Cost?

Two categories of cost apply, and they should not be blended together: mandatory USPTO government fees, and optional professional fees that depend on the situation.

9. Portfolio Cost Comparison

Government filing fees scale with the number of brands and the number of trademark classes each brand actually needs, not with company size. The figures below are illustrative base-filing costs only (excluding Statement of Use, maintenance, and any professional fees).

10. Goods vs. Services: Which Class Applies?

Depending on how a mark is actually used, Class 5 may be relevant to pharmaceutical preparations or products, while Class 44 may be relevant to medical and telemedicine services. Some telehealth product brands could plausibly implicate both: a compounded product shipped to a patient (Class 5) sold through a telemedicine service (Class 44).

The correct classification depends on the specific facts of how a company uses its mark in commerce, and this report does not recommend Class 5, Class 44, or both for any specific brand. Professional trademark analysis is the appropriate way to determine classification before filing.

11. Generic Name vs. Proprietary Brand

12. Do You Need ProductName.com?

No, but owning it can still be an asset. A proprietary product brand does not require a separate company, a separate website, or a separate domain to exist. A company can launch a named product entirely inside its existing site.

An exact-match .com is a genuinely useful optional brand asset for defensive ownership, redirects, and preventing a competitor or squatter from controlling the obvious matching domain, but it is an enhancement, not a prerequisite for the trademark strategy itself.

Section 15 shows this in practice: SermoMax™ could launch entirely at SermoMax.Cield.com, while SermoMax.com is held separately as an optional complementary asset.Illustrative, publisher-owned

13. One Master Brand, Multiple Product Brands

A telehealth company generally has two structural choices once it starts branding products at all: keep everything under one master brand, or build a portfolio of named products beneath it.

14. The ExploreTreatments Product Brand Score

To compare the strategic quality of existing telehealth product brands on brand and IP characteristics rather than marketing performance, ExploreTreatments developed a simple 100-point framework.

15. Applying the Productization Model: The Cield Portfolio

Cield™ is a master telehealth brand. Applying the Model B portfolio structure from Section 13 across every category this report covers shows the full illustrative architecture at once:

KNOXT, Oryvia Health, and the longevity pair are not required to launch together.

MyLonge™ and LongeIQ™ sit side by side under Longevity rather than stacked, because they are alternative positioning concepts for the same NAD+ category (Section 5), not a required two-step launch sequence.

Related parties currently own or control Cield.com, SermoMax.com, OryviaHealth.com, KNOXT, MyLonge.com, and LongeIQ.com. These exact-match domains are treated as additional optional assets where owned, not as requirements the architecture depends on, consistent with Section 12 above. The point of this section is not to promote these names; it is to show how the productization pattern identified in Sections 3 through 5 could translate into one master-brand-plus-product-brand portfolio.

16. When Product Branding Doesn't Make Sense

Product branding is a strategic option, not a universal rule. It may not make sense when:

• The treatment is temporary and the company has no plan to support the product long term
• The proposed name is weak, generic, or merely descriptive
• A clearance search identifies significant existing trademark conflicts
• The master brand itself lacks enough recognition to lend the sub-brand credibility
• Too many sub-brands would confuse patients rather than help them
• The treatment needs particularly prominent generic or clinical identification for safety reasons
• The incremental IP value is unlikely to justify the filing and ongoing management cost

17. Brand Differentiation Is Not Clinical Differentiation

Every named 4-in-1 ED product in this report’s brand map is a compounded medication. Compounded drugs are not individually FDA-approved, regardless of how distinctive the marketing name is. A memorable product name is a marketing and intellectual-property asset; it is not, by itself, clinical evidence.

18. 2027 Outlook

Based on the pattern found in this research, women’s HRT looks like the category most likely to see more proprietary product naming next: DirectMeds and Fem Excel have already shown the model works, and the specialist menopause brands that haven’t yet branded a specific product (Midi Health, Alloy, Evernow, Winona) have the scale to do so.

Sermorelin and NAD+ appear the least likely to change quickly. Both remain dominated by generic naming across every provider ExploreTreatments has verified, with no signal yet of a company breaking from that pattern. TRT sits in between: it is a large, competitive market with the same interchangeability problem that pushed ED providers toward branding, but no provider ExploreTreatments reviewed has made that move yet.

Methodology

• Sample: approximately 30 U.S. telehealth companies across men’s health, women’s health, weight management, and longevity, drawn from ExploreTreatments’ existing verified provider research plus independent research conducted in September 2026.
• Definition of "product brand": a consumer-facing name for a specific treatment product or program that is distinct from both the company’s own name and the generic name of the underlying medication or treatment.
• Classification methodology: each company was classified into one of six naming models (generic medication name, generic treatment/program name, descriptive product name, masterbrand extension, proprietary product brand, or proprietary vertical/sub-brand), based solely on its own public marketing.
• Trademark research methodology: this report describes general USPTO principles and current fee schedules from uspto.gov. ExploreTreatments did not run a trademark clearance search or registrability opinion on any brand name discussed, including its own illustrative names.
• The NAD+ (30 providers) and TRT (8 providers) cohorts referenced in Sections 2 and 5 are drawn directly from ExploreTreatments’ own prior published research, cited by link where referenced.
• Verified commercial brands (e.g., QMAX, QUAD, Nuvella) are distinguished throughout, including in every diagram and table, from publisher-owned illustrative concepts (Cield, KNOXT, SermoMax, Oryvia Health, MyLonge, LongeIQ), which are disclosed and never counted as independent adoption evidence.
• Limitations: this is a point-in-time snapshot of public marketing as of September 2026, not a census of every U.S. telehealth company. Company naming strategies, product lineups, and trademark filings change over time and may differ from what is reported here.

Sources

• USPTO: Trademark Fee Information
• USPTO: Trademark Strength Spectrum
• USPTO: Trademark, Patent, or Copyright
• FDA: Compounding and FDA Questions and Answers
• Official company and product websites for each telehealth brand named in this report, accessed independently in September 2026.
• ExploreTreatments’ own prior research: The State of NAD+ Telehealth 2026 and 2026 TRT Telehealth Pricing Report.

Publisher Disclosure

ExploreTreatments or related parties own, control, or are developing several names and domains used as illustrative examples throughout this report, most prominently in Section 15: Cield / Cield.com, KNOXT, SermoMax / SermoMax.com, Oryvia Health / OryviaHealth.com, MyLonge / MyLonge.com, and LongeIQ / LongeIQ.com.

These names are not included in this report’s independent industry-adoption statistics, findings, or brand map (Section 2) unless independently verified elsewhere as a commercially launched, unrelated product. Every illustrative appearance in Sections 3 through 15 is marked with an “Illustrative, publisher-owned” tag or an equivalent note. They appear only to demonstrate how the brand- architecture framework in this report could potentially be applied by a telehealth company.

ExploreTreatments may also hold affiliate relationships with some telehealth companies discussed in this report. Those relationships did not influence the naming classifications, cohort statistics, or findings above, which are determined solely by the verification methodology described. See the full advertising disclosure below.